tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['glofitamab']
#17icml . glofitamab as monotherapy by dr. m. dickinson. pivotar phase 2. refractory to first therapy 59%, to the last 85%. docr 67% 18m. pfs 72% at 18m. pfs eot 80% at 12m. crs 64% grade 3-4 4%. early cohortes huave extender fu (&gt;10mg) 24m docr 62.6% 
Happily married. Hematologist & SC Transplanter. field of interest: lymphoma-myeloma &chemoresistance biomarkers. @HematoClinicBCN @hematosantpau.@GELL01433166